Home Cart 0 Sign in  
X

[ CAS No. 100858-32-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 100858-32-0
Chemical Structure| 100858-32-0
Chemical Structure| 100858-32-0
Structure of 100858-32-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 100858-32-0 ]

Related Doc. of [ 100858-32-0 ]

Alternatived Products of [ 100858-32-0 ]

Product Details of [ 100858-32-0 ]

CAS No. :100858-32-0 MDL No. :MFCD07784363
Formula : C12H15NO3 Boiling Point : -
Linear Structure Formula :- InChI Key :MBLJFGOKYTZKMH-NSHDSACASA-N
M.W : 221.25 Pubchem ID :13438604
Synonyms :

Calculated chemistry of [ 100858-32-0 ]

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.42
Num. rotatable bonds : 4
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 62.98
TPSA : 49.77 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.85 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.33
Log Po/w (XLOGP3) : 1.13
Log Po/w (WLOGP) : 0.86
Log Po/w (MLOGP) : 1.14
Log Po/w (SILICOS-IT) : 1.13
Consensus Log Po/w : 1.32

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.94
Solubility : 2.56 mg/ml ; 0.0116 mol/l
Class : Very soluble
Log S (Ali) : -1.77
Solubility : 3.77 mg/ml ; 0.017 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.14
Solubility : 1.61 mg/ml ; 0.00726 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.63

Safety of [ 100858-32-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H317-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 100858-32-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 100858-32-0 ]
  • Downstream synthetic route of [ 100858-32-0 ]

[ 100858-32-0 ] Synthesis Path-Upstream   1~23

  • 1
  • [ 100858-32-0 ]
  • [ 192214-06-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 1997, vol. 7, # 13, p. 1773 - 1778
  • 2
  • [ 130312-02-6 ]
  • [ 100858-32-0 ]
YieldReaction ConditionsOperation in experiment
86% With recombinant Rhodococcus erythropolis DSM 43297 ketoredutase; nicotinamide adenine dinucleotide In aq. phosphate buffer; isopropyl alcohol at 50℃; for 21 h; Enzymatic reaction General procedure: The reaction mixture containing 200 mM substrate, 1mM NAD+, 5percent (v/v) 2-propanol and 10mg crude enzyme READH in 1mL potassium phosphate buffer (100mM, pH 7.0) was incubated at 50 °C. For ChKRED20, 40percent (v/v) 2-propanol and a reaction temperature of 40 °C were applied instead. The reaction was monitored by TLC, and terminated by extracting with methyl tert-butyl ether (1 mL). The organic extract was dried over anhydrous sodium sulfate and concentrated. The samples were subjected to chiral HPLC to determine the conversion and enantiomeric excess. The products were purified by silica gel column chromatography, and identified by NMR analysis, optical rotation measurements and mass spectrometry.
Reference: [1] Process Biochemistry, 2017, vol. 56, p. 90 - 97
  • 3
  • [ 501-53-1 ]
  • [ 100243-39-8 ]
  • [ 100858-32-0 ]
YieldReaction ConditionsOperation in experiment
92% With triethylamine In dichloromethane at 5 - 20℃; for 48 h; Step 1: preparation of benzyl (3S)-3-hydroxypyrrolidine-1-carboxylate. A solution of (3S)-pyrrolidin-3-ol (10.0 g, 0.12 mol) in dichloromethane (130 mL) was cooled to 5°C. Triethylamine (16.9 mL, 0.12 mol) was added, followed by drop wise addition ofbenzyl chloroformate (13.9 mL, 0.10 mol), ensuring that the temperature did not exceed5°C. The reaction mixture was then allowed to stir at ambient temperature for 48h, after which it was poured into aqueous saturated sodium bicarbonate and extracted into dichloromethane. The combined organic layers were washed with aqueous saturated sodium bicarbonate, dried over magnesium sulfate, and concentrated in vacuo. The resulting crude oil was purified by silica gel column chromatography (50percent ether hexanes followed by ether) to afford the title compound as a clear oil (14 g, 92percent).
Reference: [1] Patent: WO2014/68527, 2014, A1, . Location in patent: Page/Page column 81; 82
[2] Bioorganic and Medicinal Chemistry Letters, 1997, vol. 7, # 13, p. 1773 - 1778
  • 4
  • [ 100858-33-1 ]
  • [ 100858-32-0 ]
YieldReaction ConditionsOperation in experiment
89%
Stage #1: With sodium 2,2,2-trifluoroacetate; 2,2-difluoro-1,3-dimethyl-imidazolidine In toluene at 0 - 50℃; for 4 h;
Stage #2: With water; sodium hydrogencarbonate In toluene at 15 - 20℃; for 0.5 h;
Sodium trifluoroacetate (32.6 g) was suspended in toluene (213 g), and DFI (32.6 g) was added dropwise thereto at 0°C. The mixture was stirred at 0°C for 1 hour, and then R-CHP (44.2 g) was added thereto. The reaction solution was stirred at 0°C for 1 hour, and then at 50°C for 2 hours. The reaction solution was kept at 15°C or lower, a 5 wtpercent aqueous sodium hydrogen carbonate solution (480 g) was added dropwise to the reaction solution, which was stirred at room temperature for 30 min. Subsequently, the toluene layer was separated. The toluene layer was washed three times with water (100 g), and then concentrated under reduced pressure. To the obtained residue were added toluene (40 g) and hexane (80 g), and the mixture was crystallized at 0°C. The obtained crystal was collected by filtration, and dried at 40°C for 12 hours under reduced pressure to obtain a target compound. Amount 39.3 g Yield 89percent Stereoisomer ratio S-CHP:R-CHP=99.9:0.1 1H-NMR (toluene-d8, 400 MHz) δ 7.23-7.20 (m, 2H), 7.13-6.98 (m, 3H), 5.11-4.99 (m, 2H), 3.93 (bs, 1H), 3.46-3.12 (m, 4H), 1.65-1.45 (m, 1H), 1,45-1.30 (m, 1H) The stereoselectivity in the reaction was determined by using the concentrated residue before crystallization and using the peak area ratio of S-CHP and R-CHP under an HPLC analysis condition 6. S-CHP:R-CHP=99.8:0.2
85%
Stage #1: With hexafluoropropene-diethylamine adduct; sodium 2,2,2-trifluoroacetate In toluene at 0 - 50℃; for 4 h;
Stage #2: With water; sodium hydrogencarbonate In toluene at 15 - 20℃; for 0.5 h;
Sodium trifluoroacetate (2.04 g) was suspended in toluene (10 g), and PPDA (3.35 g) was added dropwise thereto at 0°C. The mixture was stirred at 0°C for 1 hour, and then R-CHP (1.11 g) was added thereto. The reaction solution was stirred at 0°C for 1 hour, and then at 50°C for 2 hours. To the reaction solution was added toluene (20 g), and the mixture was kept at 15°C or lower, and added dropwise to an ice-cooled, 5 wtpercent aqueous sodium hydrogen carbonate solution (30 g). The reaction solution was stirred at room temperature for 30 min, and then the toluene layer was separated. The toluene layer was washed three times with water (20 g), and then concentrated under reduced pressure to obtain a residue as a pale brown solid containing a target compound. Amount 0.94 g Yield 85percent The stereoselectivity in this reaction was determined from the peak area ratio of S-CHP and R-CHP under an HPLC analysis condition-6. Stereoisomer ratio S-CHP:R-CHP=96:4 1H-NMR (toluene-d8, 400 MHz) was consistent with that in Example 29.
78%
Stage #1: With 1,1-difluoro-N,N,N',N'-tetramethylmethanediamine; sodium 2,2,2-trifluoroacetate In toluene at 0 - 50℃; for 4 h;
Stage #2: With water; sodium hydrogencarbonate In toluene at 15 - 20℃; for 0.5 h;
Sodium trifluoroacetate (2.04 g) was suspended in toluene (10 g), and BDDF (2.07 g) was added dropwise thereto at 0°C. The mixture was stirred at 0°C for 1 hour, and then R-CHP (1.11 g) was added thereto. The reaction solution was stirred at 0°C for 1 hour, and then at 50°C for 2 hours. To the reaction solution was added toluene (20 g), and the mixture was kept at 15°C or lower, and added dropwise to an ice-cooled, 5 wtpercent aqueous sodium hydrogen carbonate solution (30 g). The reaction solution was stirred at room temperature for 30 min, and then the toluene layer was separated. The toluene layer was washed three times with water (20 g), and then concentrated under reduced pressure to obtain a residue as a pale brown solid containing a target compound. Amount 0.87 g Yield 78percent The stereoselectivity in this reaction was determined from the peak area ratio of S-CHP and R-CHP under an HPLC analysis condition-6. Stereoisomer ratio S-CHP:R-CHP=94:6 1H-NMR (toluene-d8, 400 MHz) was consistent with that in Example 29.
Reference: [1] Patent: EP2039680, 2009, A1, . Location in patent: Page/Page column 43
[2] Patent: EP2039680, 2009, A1, . Location in patent: Page/Page column 44
[3] Patent: EP2039680, 2009, A1, . Location in patent: Page/Page column 45-46
[4] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 5, p. 1265 - 1268
[5] Journal of Organic Chemistry, 2001, vol. 66, # 25, p. 8513 - 8517
[6] Patent: WO2004/43940, 2004, A1,
[7] Patent: WO2005/108382, 2005, A1,
[8] Patent: WO2005/116029, 2005, A1,
  • 5
  • [ 130403-93-9 ]
  • [ 100858-32-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 5, p. 1265 - 1268
[2] Patent: WO2004/43940, 2004, A1, . Location in patent: Page 47
[3] Patent: WO2005/116029, 2005, A1, . Location in patent: Page/Page column 50-51
[4] Patent: WO2005/108382, 2005, A1, . Location in patent: Page/Page column 38
  • 6
  • [ 501-53-1 ]
  • [ 122536-94-1 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Patent: US5977381, 1999, A,
  • 7
  • [ 960508-13-8 ]
  • [ 100858-32-0 ]
Reference: [1] Patent: EP2039680, 2009, A1, . Location in patent: Page/Page column 42
  • 8
  • [ 501-53-1 ]
  • [ 122536-94-1 ]
  • [ 100858-32-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1992, vol. 35, # 10, p. 1764 - 1773
[2] Organic and Biomolecular Chemistry, 2003, vol. 1, # 9, p. 1498 - 1502
  • 9
  • [ 501-53-1 ]
  • [ 100858-32-0 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 25, p. 8513 - 8517
[2] Patent: WO2004/43940, 2004, A1,
[3] Patent: WO2005/108382, 2005, A1,
[4] Patent: WO2005/116029, 2005, A1,
  • 10
  • [ 95656-88-5 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Chemical Communications, 2017, vol. 53, # 3, p. 509 - 512
  • 11
  • [ 31970-04-4 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Journal of the American Chemical Society, 1986, vol. 108, # 8, p. 2049 - 2054
  • 12
  • [ 108-05-4 ]
  • [ 95656-88-5 ]
  • [ 100858-32-0 ]
Reference: [1] Tetrahedron Asymmetry, 2007, vol. 18, # 3, p. 435 - 442
  • 13
  • [ 108-22-5 ]
  • [ 95656-88-5 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Advanced Synthesis and Catalysis, 2011, vol. 353, # 13, p. 2321 - 2327
  • 14
  • [ 25070-74-0 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Advanced Synthesis and Catalysis, 2010, vol. 352, # 18, p. 3380 - 3390
  • 15
  • [ 31970-04-4 ]
  • [ 100858-32-0 ]
Reference: [1] Heterocycles, 1989, vol. 28, # 1, p. 283 - 294
  • 16
  • [ 100858-32-0 ]
  • [ 122536-73-6 ]
Reference: [1] Journal of Medicinal Chemistry, 1992, vol. 35, # 10, p. 1764 - 1773
  • 17
  • [ 501-53-1 ]
  • [ 122536-94-1 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Patent: US5977381, 1999, A,
  • 18
  • [ 95656-88-5 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Chemical Communications, 2017, vol. 53, # 3, p. 509 - 512
  • 19
  • [ 31970-04-4 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Journal of the American Chemical Society, 1986, vol. 108, # 8, p. 2049 - 2054
  • 20
  • [ 108-22-5 ]
  • [ 95656-88-5 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Advanced Synthesis and Catalysis, 2011, vol. 353, # 13, p. 2321 - 2327
  • 21
  • [ 25070-74-0 ]
  • [ 100858-32-0 ]
  • [ 100858-33-1 ]
Reference: [1] Advanced Synthesis and Catalysis, 2010, vol. 352, # 18, p. 3380 - 3390
  • 22
  • [ 100858-32-0 ]
  • [ 122536-75-8 ]
Reference: [1] Journal of Medicinal Chemistry, 1992, vol. 35, # 10, p. 1764 - 1773
  • 23
  • [ 100858-32-0 ]
  • [ 130312-02-6 ]
YieldReaction ConditionsOperation in experiment
88% With tetrapropylammonium perruthennate; 4-methylmorpholine N-oxide In dichloromethane for 2 h; Molecular sieve; Inert atmosphere Step 2: preparation of benzyl 3-oxopyrrolidine-1-carboxylate. To a solution ofbenzyl (3S)-3-hydroxypyrrolidine-1-carboxylate (7.5 g, 33.9 mmol) in dichloromethane(1.2 L) was added 4-methylmorpholine N-oxide (5.96 g, 50.0 mmol), tetrapropylammonium perruthenate (0.60 g, 1 .7 mmol), and 4 A molecular sieves (7.0 g). The reaction mixture was allowed to stir under nitrogen for 2 h, after which it was filtered through a silica gel plug and eluted with diethyl ether. The filtrate canconcentrated to afford the title compound as clear oil (6.5 g, 88percent).
Reference: [1] Patent: WO2014/68527, 2014, A1, . Location in patent: Page/Page column 82
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 100858-32-0 ]

Aryls

Chemical Structure| 100858-34-2

[ 100858-34-2 ]

(R)-Benzyl 3-hydroxypiperidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 95798-22-4

[ 95798-22-4 ]

Benzyl 3-hydroxypiperidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 95798-23-5

[ 95798-23-5 ]

Benzyl 4-hydroxypiperidine-1-carboxylate

Similarity: 0.90

Chemical Structure| 648418-25-1

[ 648418-25-1 ]

Benzyl 4-hydroxyazepane-1-carboxylate

Similarity: 0.90

Chemical Structure| 128117-22-6

[ 128117-22-6 ]

1-Cbz-3-Hydroxyazetidine

Similarity: 0.90

Alcohols

Chemical Structure| 100858-34-2

[ 100858-34-2 ]

(R)-Benzyl 3-hydroxypiperidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 95798-22-4

[ 95798-22-4 ]

Benzyl 3-hydroxypiperidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 95798-23-5

[ 95798-23-5 ]

Benzyl 4-hydroxypiperidine-1-carboxylate

Similarity: 0.90

Chemical Structure| 648418-25-1

[ 648418-25-1 ]

Benzyl 4-hydroxyazepane-1-carboxylate

Similarity: 0.90

Chemical Structure| 128117-22-6

[ 128117-22-6 ]

1-Cbz-3-Hydroxyazetidine

Similarity: 0.90

Amides

Chemical Structure| 100858-34-2

[ 100858-34-2 ]

(R)-Benzyl 3-hydroxypiperidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 95798-22-4

[ 95798-22-4 ]

Benzyl 3-hydroxypiperidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 95798-23-5

[ 95798-23-5 ]

Benzyl 4-hydroxypiperidine-1-carboxylate

Similarity: 0.90

Chemical Structure| 648418-25-1

[ 648418-25-1 ]

Benzyl 4-hydroxyazepane-1-carboxylate

Similarity: 0.90

Chemical Structure| 128117-22-6

[ 128117-22-6 ]

1-Cbz-3-Hydroxyazetidine

Similarity: 0.90

Related Parent Nucleus of
[ 100858-32-0 ]

Aliphatic Heterocycles

Chemical Structure| 100858-34-2

[ 100858-34-2 ]

(R)-Benzyl 3-hydroxypiperidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 95798-22-4

[ 95798-22-4 ]

Benzyl 3-hydroxypiperidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 95798-23-5

[ 95798-23-5 ]

Benzyl 4-hydroxypiperidine-1-carboxylate

Similarity: 0.90

Chemical Structure| 128117-22-6

[ 128117-22-6 ]

1-Cbz-3-Hydroxyazetidine

Similarity: 0.90

Chemical Structure| 1217619-19-6

[ 1217619-19-6 ]

(S)-Benzyl 3-(aminomethyl)pyrrolidine-1-carboxylate hydrochloride

Similarity: 0.84

Pyrrolidines

Chemical Structure| 72597-18-3

[ 72597-18-3 ]

(R)-Benzyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate

Similarity: 0.86

Chemical Structure| 1086394-87-7

[ 1086394-87-7 ]

Benzyl 2,6-diazaspiro[3.4]octane-2-carboxylate

Similarity: 0.84

Chemical Structure| 1217619-19-6

[ 1217619-19-6 ]

(S)-Benzyl 3-(aminomethyl)pyrrolidine-1-carboxylate hydrochloride

Similarity: 0.84

Chemical Structure| 1217726-65-2

[ 1217726-65-2 ]

(R)-Benzyl 3-(aminomethyl)pyrrolidine-1-carboxylate hydrochloride

Similarity: 0.84

Chemical Structure| 799767-82-1

[ 799767-82-1 ]

Benzyl 3-bromo-4-hydroxypyrrolidine-1-carboxylate

Similarity: 0.83